United Therapeutics (UTHR) Misses Q3 EPS by 50c, Beats on Revenue

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to United Therapeutics (UTHR) Misses Q3 EPS by 50c, Beats on Revenue

United Therapeutics Corporation Reports Third Quarter 2026 Financial Results

November 4, 2026 6:30 AM EST

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2026. Total revenues in the third quarter of 2026 increased by four percent year-over-year to $832.5 million, compared to $799.5 million in the third quarter of 2025.

United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies designed to exponentially increase the number of patients we can serve, said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics.

Our record third... More